Akebia Therapeutics
AKBA
119 hedge funds and large institutions have $593M invested in Akebia Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 16 reducing their positions, and 23 closing their positions.
891% more call options, than puts
Call options by funds: $2.2M | Put options by funds: $222K
250% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 16
51% more capital invested
Capital invested by funds: $392M → $593M (+$202M)
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
0% more funds holding
Funds holding: 119 → 119 (0)
0.19% less ownership
Funds ownership: 64.17% → 63.98% (-0.19%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.5M |
| 2 |
PA
Perceptive Advisors
New York
|
+$8.15M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$7.19M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$6.09M |
| 5 |
Renaissance Technologies
New York
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$12M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$7.41M |
| 4 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$4.65M |
| 5 |
First Manhattan
New York
|
-$4.24M |
AKBA Hedge Fund Activity: Q3 2017 in Review
119 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2017, worth a combined $593M — up 51% from $392M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AKBA positions and 23 closed out — a net gain of 1 holder — while 56 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $12M sold.
- 119 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $593M of Akebia Therapeutics stock for Q3 2017, up 51% quarter-over-quarter.
- 24 funds opened new Akebia Therapeutics positions in Q3 2017 and 23 closed out, a net change of +1 holder.
- The largest Akebia Therapeutics buyer in Q3 2017 was BlackRock, an estimated $15.5M added.
- The largest Akebia Therapeutics seller in Q3 2017 was RA Capital Management, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2017.